Reinfuse Chyme • Help the Patient

US FDA Breakthrough devices enabling chyme reinfusion in patients with complex intestinal diseases

Watch the video

The InsidesTM Company is the developer and manufacturer of therapeutic chyme reinfusion solutions for patients with intestinal failure, resulting from enterocutaneous fistulas or
high-output enterostomies.

The InsidesTM Company's first product, The InsidesTM Systemfi, is a CE-marked medical device that enables chyme and its nutritional contents to be refed into the distal intestine, rather than being discarded from the patient's ostomy appliance.

The InsidesTM Systemfi has been granted "Breakthrough Device Designation" by the US FDA. The InsidesTM Systemfi is now commercially available in the United Kingdom, Europe, and New Zealand. *The InsidesTM Systemfi is not currently approved for sales in the United States. Caution - Investigational Device, Limited by Federal Law to Investigational Use

*The InsidesTM Systemfi is not currently approved for sales in the United States.
Caution - Investigational Device, Limited by Federal Law to Investigational Use

Partnering with the world’s leading centres for colorectal diseases

The InsidesTM Company is founded by world-leading pioneers in gut nutrition, and commercialised by med-tech veterans. The InsidesTM Systemfi is now being used in multiple key international intestinal failure sites.

Please contact us today to learn about how our device can impact your patient's journey to recovery.

Professor Ian Bisset
Co-Founder & Chief Medical Officer

Professor Ian Bisset

Professor Ian Bisset

Professor Ian Bisset

Associate Professor
Greg O’Grady
Co-Founder & Chief Scientific Officer

“The InsidesTM Systemfi is revolutionising recovery times & patient well-being.”

For the effective chyme reinfusion treatment of enterocutaneous fistulas and high-output enterostomies

*The InsidesTM Systemfi is not currently approved for sales in the United States.
Caution - Investigational Device, Limited by Federal Law to Investigational Use

Under the standard care pathway, patients recovering from colorectal surgery resulting from Colorectal Cancer, and Inflammatory Bowel Disease will have an enterostomy created to divert intestinal contents
(chyme) away from the surgical site (anastomosis) as it heals.

The enterostomy is typically left open for 6-12 months, and during this time, the chyme that is collected is disposed into the toilet. This results in complications, readmissions, and reduced quality of life.

The InsidesTM Company’s first product, The InsidesTM Systemfi, is a chyme reinfusion solution, which enables diverting enterostomy, and enterocutaneous patients to reinfuse chyme (the contents of their ostomy appliance), back into their intestine, allowing them to recommence oral feeding and reduce length of stay in hospital.

Restart oral nutrition

Positive weight gain

Reduce risk of line sepsis

Recovery of liver enzymes

Reduce dehydration & risk of renal impairment

Reduced days in hospital

Reduced use of high cost therapy

Reduced cases of readmission

Reduced rate of mortality

Key Clinical Benefits of Chyme Reinfusion

Earlier return to oral feeding1-2

Patients able to recommence oral feeding

Improved nutritional outcome2

Increase in nutritional risk index by 10.9 (± 9.5) with a 85% reduction in intestinal losses

Improved restoration of gut function3

Reverse gut atrophy and inflammation and improved gut microbiome

Improved renal function4

Prevents dehydration and reduces the potential for chronic kidney disease

Improved liver function5

53% reduction in plasma liver test abnormalities

Wean off Parenteral Nutrition2

>91% of patients weaned off parenteral nutrition within a median of 2 days (± 9)

References: 

1. Sharma P, Davidson R, Davidson J, Keane C, Liu C, Ritchie SR, et al. Novel chyme reinfusion device for gastrointestinal fistulas and stomas: feasibility study. Br J Surg [Internet]. 2020 Apr 18; Available from: http://doi.wiley.com/10.1002/bjs.11516
2. Picot D, Layec S, Dussaulx L, Trivin F, Thibault R. Chyme reinfusion in patients with intestinal failure due to temporary double enterostomy: A 15-year prospective cohort in a referral centre. Clin Nutr [Internet]. 2017 Apr;36(2):593–600. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0261561416300668
3. Pflug AM, Utiyama EM, Fontes B, Faro M, Rasslan S. Continuous reinfusion of succus entericus associated with fistuloclysis in the management of a complex jejunal fistula on the abdominal wall. Int J Surg Case Rep [Internet]. 2013;4(8):716–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S221026121300179X
4. Fielding A, Woods R, Moosvi SR, Wharton RQ, Speakman CTM, Kapur S, et al. Renal impairment after ileostomy formation: a frequent event with long‐term consequences. Color Dis [Internet]. 2019 Oct 17;codi.14866. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/codi.14866
5. Layec S, Seynhaeve E, Trivin F, Carsin-Mahé M, Dussaulx L, Picot D. Management of entero-atmospheric fistulas by chyme reinfusion: A retrospective study. Clin Nutr [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0261561420301485

Emma Ludlow
Clinical Nurse Specialist Ostomy

"The InsidesTM Systemfi allows me to support, and optimise my patient’s journey to recovery."

The Insides Company Partners